Metastatic TNBC: ipatasertib extends PFS benefit of front-line paclitaxel

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
Takeaway
  • In patients with metastatic triple-negative breast cancer (TNBC), median PFS is prolonged who received the novel drug ipatasertib plus paclitaxel (Abraxane) vs placebo plus paclitaxel.
Why this matters
  • Because metastatic TNBC has a poor prognosis, this phase 2 trial offers hope for a...